Skip to content
Inciteful Med

Treatments and Clinical Trials for GNE Myopathy

Last updated:

There is currently no cure for GNE myopathy, but treatment includes supportive care like physical therapy and ankle-foot orthoses (AFOs) to manage foot drop. Emerging therapies, including substrate replacement drugs like Acenobel and ManNAc, aim to address the underlying sialic acid deficiency.

Key Takeaways

  • • Standard care for GNE myopathy focuses on physical therapy, fall prevention, and orthotics like AFOs to manage foot drop.
  • • Aceneuramic acid (Acenobel) was approved in Japan in 2024 to treat GNE myopathy but is not FDA-approved globally.
  • • Clinical trials are ongoing for ManNAc, a precursor molecule that helps the body produce missing sialic acid.
  • • Gene therapy for GNE myopathy is currently in the preclinical stage showing proof-of-concept success in laboratory models.
  • • Regular monitoring of upper extremity strength and respiratory function is vital to tracking disease progression and treatment efficacy.

Managing GNE Myopathy currently involves a two-part approach: maximizing your function through supportive care and looking toward the rapidly advancing field of disease-modifying therapies. While there is not yet a global “cure,” the landscape of treatment is evolving, providing a new roadmap for patients and doctors to discuss.

Standard of Care: Supporting Your Independence

Because GNE Myopathy progresses slowly, the primary goal of current treatment is to keep you mobile and safe for as long as possible [1].

  • Physical Therapy (PT) & Fall Prevention: A specialized therapist can help you maintain flexibility and strength. Because of the unique biomechanics of foot drop combined with strong thighs, a major focus of PT must be fall prevention [2][3].
  • Orthotics (AFOs): To manage foot drop, many patients use Ankle-Foot Orthoses (AFOs). These are lightweight braces that hold the foot in a neutral position, preventing you from “tripping over your toes” and drastically reducing the risk of falls [3][4].
  • Monitoring: Your care team should regularly check your upper extremity strength (arms and hands) and respiratory function, as these are the key areas used to measure how well treatments are working in clinical trials [5][4].

Substrate Replacement: Fixing the “Missing Sugar”

The most advanced treatments aim to fix the root cause of the disease—hyposialylation (the lack of sialic acid) [6].

  • Aceneuramic Acid (Acenobel/Acediur):
    • The Breakthrough in Japan: In March 2024, Japan’s PMDA became the first regulatory body to approve this extended-release form of sialic acid for the treatment of GNE Myopathy [7][6]. In Japanese trials, a dose of 6 grams per day was shown to slow the decline of muscle strength in the arms and hands compared to a placebo [8][9].
    • The Global Reality: While this is a huge milestone, it is important to know the global context to manage expectations. Large international Phase III clinical trials (conducted in the US and Europe) unfortunately failed to show significant overall improvement compared to a placebo [10][11]. As a result, the drug is not approved by the FDA or EMA, and access outside of Japan is currently extremely limited [10].
  • ManNAc (N-acetylmannosamine): This is a “precursor” molecule, essentially a building block that the body turns into sialic acid [12].
    • Status: Clinical trials (such as NCT02346461) have shown that ManNAc can successfully increase sialic acid levels in the blood and muscles [13]. Preliminary data suggested it might help slow the rate of muscle decline, and research is ongoing globally to confirm its long-term benefits [13].

The Future: Gene Therapy

While substrate replacement adds the “missing sugar” daily, gene therapy aims to fix the “factory” itself.

  • The Goal: Researchers are using Adeno-Associated Virus (AAV) vectors to deliver a healthy, functional copy of the GNE gene directly into muscle cells [14].
  • Current Status: This work is currently in the preclinical stage, meaning it has shown “proof-of-concept” success in laboratory models and is being refined for future human trials [14][15].

While the road to a universally available treatment has had ups and downs, the recent activity in clinical trials signals that this “ultra-rare” disease is now a major focus of medical research [11].

Frequently Asked Questions

Is there a cure for GNE myopathy?
Currently, there is no global cure for GNE myopathy. Treatment focuses on supportive care like physical therapy and orthotics to maximize mobility, alongside ongoing clinical trials for disease-modifying therapies.
What is Acenobel and is it available everywhere?
Acenobel (aceneuramic acid) is a substrate replacement therapy approved in Japan to slow muscle decline in GNE myopathy. However, it is not currently approved by the FDA or EMA, making access extremely limited outside of Japan.
How do ankle-foot orthoses (AFOs) help with GNE myopathy?
AFOs are lightweight braces that hold the foot in a neutral position. They help manage foot drop, prevent you from tripping over your toes, and significantly reduce the risk of dangerous falls.
What is the status of gene therapy for GNE myopathy?
Gene therapy for GNE myopathy is currently in the preclinical stage. Researchers are successfully using viral vectors to deliver functional copies of the GNE gene into muscle cells in laboratory models, with hopes for future human trials.
What is ManNAc and how might it help?
ManNAc is a precursor building block that the body converts into sialic acid, which is deficient in patients with GNE myopathy. Ongoing global clinical trials are evaluating if taking ManNAc can safely increase sialic acid levels and slow the rate of muscle decline.

Questions for Your Doctor

  • • Are you familiar with the recent approval of Aceneuramic acid (Acenobel) in Japan, and is there any expanded access program for it in our region?
  • • What is the current status of the ManNAc clinical trials globally, and am I a candidate for any upcoming phases?
  • • Can you refer me to a physical therapist who has experience with 'foot drop' and fall prevention?
  • • Is there a patient registry I should join to be notified about future gene therapy trials?
  • • How can we monitor my upper extremity strength and respiratory function to see if my current supportive care is working?

Questions for You

  • • How is my mobility currently affecting my daily life, and would tools like AFOs help me stay more active and prevent falls?
  • • Am I willing to travel or participate in long-term clinical trials if a new therapy becomes available?
  • • Have I connected with GNE Myopathy advocacy groups to stay updated on the latest research and drug approvals?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    [GNE myopathy].

    Urtizberea JA, Béhin A

    Medecine sciences : M/S 2015; (31 Spec No 3()):20-7 doi:10.1051/medsci/201531s306.

    PMID: 26546927
  2. 2

    Slowly progressive distal muscle weakness: neuropathy or myopathy?

    Nahari Y, Abbas A, Curtis E, Jacob S

    BMJ case reports 2019; (12(4)) doi:10.1136/bcr-2018-226903.

    PMID: 30948392
  3. 3

    GNE myopathy - A cross-sectional study on spatio-temporal gait characteristics.

    Gomez G, Khanna M, Gupta A, et al.

    Neuromuscular disorders : NMD 2019; (29(12)):961-967 doi:10.1016/j.nmd.2019.11.003.

    PMID: 31787465
  4. 4

    Patient reported outcomes in GNE myopathy: incorporating a valid assessment of physical function in a rare disease.

    Slota C, Bevans M, Yang L, et al.

    Disability and rehabilitation 2018; (40(10)):1206-1213 doi:10.1080/09638288.2017.1283712.

    PMID: 28637129
  5. 5

    Progression of GNE Myopathy Based on the Patient-Reported Outcome.

    Park YE, Kim DS, Choi YC, Shin JH

    Journal of clinical neurology (Seoul, Korea) 2019; (15(3)):275-284 doi:10.3988/jcn.2019.15.3.275.

    PMID: 31286697
  6. 6

    Decoding GNE Myopathy: From Molecular Basis to Therapeutic Advances.

    Yoshioka W, Noguchi S, Nishino I

    Annals of Indian Academy of Neurology 2025; (28(5)):631-639 doi:10.4103/aian.aian_837_25.

    PMID: 41082181
  7. 7

    Ultra-Orphan drug development for GNE Myopathy: A synthetic literature review and meta-analysis.

    Suzuki N, Mori-Yoshimura M, Nishino I, Aoki M

    Journal of neuromuscular diseases 2025; (12(2)):183-194 doi:10.1177/22143602241296226.

    PMID: 39973407
  8. 8

    Phase II/III Study of Aceneuramic Acid Administration for GNE Myopathy in Japan.

    Suzuki N, Mori-Yoshimura M, Katsuno M, et al.

    Journal of neuromuscular diseases 2023; (10(4)):555-566 doi:10.3233/JND-230029.

    PMID: 37125562
  9. 9

    Aceneuramic Acid Extended Release Administration Maintains Upper Limb Muscle Strength in a 48-week Study of Subjects with GNE Myopathy: Results from a Phase 2, Randomized, Controlled Study.

    Argov Z, Caraco Y, Lau H, et al.

    Journal of neuromuscular diseases 2016; (3(1)):49-66 doi:10.3233/JND-159900.

    PMID: 27854209
  10. 10

    A phase 3 randomized study evaluating sialic acid extended-release for GNE myopathy.

    Lochmüller H, Behin A, Caraco Y, et al.

    Neurology 2019; (92(18)):e2109-e2117 doi:10.1212/WNL.0000000000006932.

    PMID: 31036580
  11. 11

    [Aceneuraminic acid for distal myopathy].

    Aoki M

    Nihon yakurigaku zasshi. Folia pharmacologica Japonica 2025; (160(1)):48-52 doi:10.1254/fpj.24090.

    PMID: 39756906
  12. 12

    Safety, pharmacokinetics and sialic acid production after oral administration of N-acetylmannosamine (ManNAc) to subjects with GNE myopathy.

    Xu X, Wang AQ, Latham LL, et al.

    Molecular genetics and metabolism 2017; (122(1-2)):126-134 doi:10.1016/j.ymgme.2017.04.010.

    PMID: 28641925
  13. 13

    Safety and efficacy of N-acetylmannosamine (ManNAc) in patients with GNE myopathy: an open-label phase 2 study.

    Carrillo N, Malicdan MC, Leoyklang P, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2021; (23(11)):2067-2075 doi:10.1038/s41436-021-01259-x.

    PMID: 34257421
  14. 14

    Pre Clinical Assessment of AAVrh74.MCK.GNE Viral Vector Therapeutic Potential: Robust Activity Despite Lack of Consistent Animal Model for GNE Myopathy.

    Mitrani-Rosenbaum S, Yakovlev L, Becker Cohen M, et al.

    Journal of neuromuscular diseases 2022; (9(1)):179-192 doi:10.3233/JND-210755.

    PMID: 34806613
  15. 15

    Development of Assays to Measure GNE Gene Potency and Gene Replacement in Skeletal Muscle.

    Zygmunt DA, Lam P, Ashbrook A, et al.

    Journal of neuromuscular diseases 2023; (10(5)):797-812 doi:10.3233/JND-221596.

    PMID: 37458043

This page provides informational content about GNE myopathy treatments and clinical trials. Always consult your neurologist or healthcare provider before altering your care plan or pursuing trial enrollment.

Stay up to date

Get notified when new research about GNE myopathy is published.

No spam. Unsubscribe anytime.